{"filing":{"accession_number":"0001104659-26-097094","cik":"0001671502","ticker":"QNRX","company_name":"Quoin Pharmaceuticals, Ltd.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623115d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/tm2623115d1_8k.htm"},"events":[{"id":27881,"run_id":25457,"accession_number":"0001104659-26-097094","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Q2 2026 financial results for Quoin Pharmaceuticals. The filing explicitly states \"On August 14, 2026 Quoin Pharmaceuticals Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains consolidated balance sheets, statements of operations, and loss per ADS metrics for the periods ended June 30, 2026 and 2025, along with operational highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29588,"accession_number":"0001104659-26-097094","item_number":"2.02","item_title":"Results of Operations","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Quoin Pharmaceuticals. The filing explicitly states \"On August 14, 2026 Quoin Pharmaceuticals Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains consolidated balance sheets, statements of operations, and loss per ADS metrics for the periods ended June 30, 2026 and 2025, along with operational highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:17:58.641920+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29588,"accession_number":"0001104659-26-097094","item_number":"2.02","item_title":"Results of Operations","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Quoin Pharmaceuticals. The filing explicitly states \"On August 14, 2026 Quoin Pharmaceuticals Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains consolidated balance sheets, statements of operations, and loss per ADS metrics for the periods ended June 30, 2026 and 2025, along with operational highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:17:58.641920+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-08-14"}]}